“It could provide the groundwork for future studies with antibody-drug conjugates, including T-DXd, for patients with early-stage breast cancer.”

EGFR  exon20ins have regularly demonstrated resistance to classical EGFR inhibition.

A total of 18.2% of combination-treated participants required a dose reduction of any drug and 6.8% discontinued treatment due to AEs.

The study drugs, except for cisplatin which was only administered for the first four cycles, could be given for up to 24 months.

That is called the G1202R resistance mutation, and those ALK resistance mutation, they have different percentage of occurrence depending on the type of drug.

Patients previously treated with neither fulvestrant nor exemestane were given investigators’ choice of either of these drugs, but fulvestrant was encouraged.

Outlining the background to the study, he explained that “the [AR] axis remains activated and is often responsible for cancer progression in men with CRPC evolving after drugs such as abiraterone and enzalutamide.”

Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR -mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors.

US researchers have identified diverse molecular and histologic mechanisms of acquired resistance to KRAS G12C inhibitors in people with cancer.

Three early-phase studies presented at the IASLC 2020 World Conference on Lung Cancer point to the potential of antibody–drug conjugates for the treatment of different populations of patients with advanced non-small-cell lung cancer.

Early results suggest that a novel antibody–drug conjugate directed against HER3 has antitumor activity and manageable safety in patients with EGFR -mutated metastatic non-small-cell lung cancer and acquired resistance to EGFR–tyrosine kinase inhibitors.

Subbiah concluded: “I encourage all cancer patients to undergo genomic testing, as tumors with rare genomic aberrations may have effective drugs that are in clinical trials that could be beneficial to them.”

Immunotherapy is a potentially transformative treatment, but to receive that benefit, you must receive the drug.

A total of 47.0% of patients in the pyrotinib group required dose modification due to AEs, 61.9% needed a treatment interruption, and 3.0% discontinued one or both drugs.

Several clinical trials with this drug are ongoing for PCa.

They add that “the distinct side-effect profile of ensartinib suggests that the drug could be a treatment option for patients who are intolerant to other ALK TKIs.”

He said, however, that certain questions remain to be answered, such as whether the activity of the drug differs between KIF5B and non- KIF5B fusions, and additional data on intracranial activity and resistance are awaited.

The investigators also note that the “[i]ncidence and severity of adverse events of interest were consistent with the known toxicity profile of both drugs.”

Two grade 5 events that were felt to be possibly related to the study drugs also occurred: one case of pneumonia and one of neutropenic sepsis.

Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.